Search clinical trials for: Rivaroxaban (BAY 59-7939)

Total 132 results

Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Venous Thrombosis | Pediatrics

Italy, United States, Austria, Australia, Canada, France, Switzerland, Germany, Israel, Ireland
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Non-valvular Atrial Fibrillation (NVAF)

Japan
Bayer

Withdrawn

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (XYRIS)

Total Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
Bayer

Completed

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Canada, United States, Germany, United Kingdom, France, Netherlands
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Bayer
Janssen Research & Development, LLC

Completed

Real-world Dosing Patterns of Rivaroxaban in the United States

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates (Einstein Jr)

Thromboembolism

Spain, Austria, Israel, Italy, France, Turkey, Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Use of Direct Oral Anticoagulants in UK

Stroke

United Kingdom
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Bayer
Janssen Research & Development, LLC

Completed

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes (RIVA-DM)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Dose-confirmatory Bridging Study in Total Hip Replacement

Venous Thromboembolism

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Dose-confirmatory Bridging Study in Total Knee Replacement

Venous Thromboembolism

Japan
Bayer

Completed

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Venous Thromboembolism

Italy, Spain, Poland, United States, Czech Republic, Canada, Denmark, Netherlands, Belgium, Chile, Slovakia, Hungary, Austria, France, Germany, South Africa, Sweden, Turkey, Colombia, Israel, Mexico, Argentina, Norway, Brazil, Lithuania, ... and more
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. (RECORD 4)

Venous Thromboembolism

Poland, United States, India, Denmark, Canada, Sweden, Bulgaria, Israel, Lithuania, Norway, Pakistan, Mexico, Sri Lanka
Bayer

Completed

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer

Completed

Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXaHIP-OD)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, Norway, United Kingdom, France
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pulmonary Embolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Switzerland, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Estonia, Thailand, Brazil, Germany, Korea, Republic... and more
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Bayer
Janssen Research & Development, LLC; Colorado Prevention Center

Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

Peripheral Artery Disease

Poland, Belgium, France, Spain, China, Korea, Republic of, United States, Switzerland, Estonia, Portugal, Japan, Hungary, Canada, Netherlands, Finland, Austria, United Kingdom, Germany, Czechia, Thailand, Brazil, Denmark, Italy, Russian... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Pharmacokinetics

Germany
Bayer

Completed

ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)

Thromboembolism | Prevention

Belgium, Denmark, Austria, Germany, Netherlands, Poland, Sweden, Israel, France, Norway, United Kingdom
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (RECORD 2)

Venous Thromboembolism | Prevention

Denmark, Italy, China, Indonesia, Colombia, Portugal, United States, Australia, Korea, Republic of, Taiwan, Canada, Estonia, New Zealand, Brazil, Mexico, South Africa, Peru, United Kingdom, Latvia, India, Lithuania, Sweden, Norway
Bayer
Janssen Research & Development, LLC

Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA LEA)

Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Biological Availability

Germany
Bayer
Janssen Research & Development, LLC

Not yet recruiting

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) (XAPAEDUS)

Venous Thromboembolism | Children Under 2 Years

Spain, Sweden, Denmark, France
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
Bayer

Completed

Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXa-HIP2)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, France, Norway, United Kingdom
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Netherlands
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Bayer

Completed

Anticoagulation Preference by AF Patients Study (PRiSMA-AF)

Atrial Fibrillation

Switzerland
Janssen Research & Development, LLC
Harvard Medical School (HMS and HSDM); Bayer; Duke Clinical Research Institute

Completed

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1)

Acute Coronary Syndrome

United States, France, Poland, Ukraine, Belgium, Spain, Argentina, Bulgaria, Russian Federation, Turkey, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Australia, Hungary, Sweden, Czechia, Denmark
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Venous Thromboembolism (VTE)

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Pulmonary Embolism

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA (RIVA-F)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (X-VERT)

Atrial Fibrillation

Belgium, France, Spain, China, Italy, United States, Canada, South Africa, Portugal, Singapore, Germany, Greece, Netherlands, United Kingdom, Brazil, Denmark, Finland
Bayer
Janssen, LP

Completed

Real-Life Evidence on Stroke Prevention in SPAF (RELIEF)

Atrial Fibrillation (Prevention of Stroke)

Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (BROTHER)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

Nonvalvular Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Atrial Fibrillation

Spain

Search clinical trials for: Rivaroxaban (BAY 59-7939)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations